DDInter1085 DDInter1376
Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R).
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Lomitapide {u} (Compound) resembles {v} (Compound) Antrafenine
Lomitapide {u} (Compound) binds {v} (Gene) CYP3A4
Lomitapide {u} (Compound) is included by {v} (Pharmacologic Class) P-Glycoprotein Inhibitors
Lomitapide {u} (Compound) causes {v} (Side Effect) Xanthoma
Lomitapide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Lomitapide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apixaban
Lomitapide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Olaparib
Lomitapide {u} may lead to a major life threatening interaction when taken with {v} Terbinafine
Lomitapide {u} may lead to a major life threatening interaction when taken with {v} Nintedanib
Lomitapide {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fexofenadine
Lomitapide (Compound) resembles Antrafenine (Compound)
Lomitapide (Compound) binds CYP3A4 (Gene)
Lomitapide (Compound) is included by P-Glycoprotein Inhibitors (Pharmacologic Class)
Lomitapide (Compound) causes Xanthoma (Side Effect)
Lomitapide may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Lomitapide may cause a moderate interaction that could exacerbate diseases when taken with Apixaban
Lomitapide may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Lomitapide may lead to a major life threatening interaction when taken with Terbinafine
Lomitapide may lead to a major life threatening interaction when taken with Nintedanib
Lomitapide (Compound) resembles Fexofenadine (Compound) and Lomitapide may cause a moderate interaction that could exacerbate diseases when taken with Fexofenadine